MIR124-2 (MicroRNA 124-2)

In conclusion, the ASCL1/ZNF582 methylation assay accurately detects high-grade VIN and vulvar cancer, while minimizing the detection of benign and low-grade lesions, indicating its clinical value.

Background: HER2-positive breast cancer patients receiving chemotherapy and targeted therapy (including anthracyclines and trastuzumab) face an elevated risk of cardiotoxicity, which can lead to long-term cardiovascular complications... Circulating miRNAs show promise as biomarkers for predicting cardiotoxicity in breast cancer patients. Machine learning approaches may enhance miRNA-based risk stratification, enabling personalized monitoring and early cardioprotective interventions.

The functional analysis revealed pathways significantly related to cancer progression. Employing systems biology approaches with holistic insight can identify essential genes and their regulation as possibilities for further experimental testing.

Our findings indicate that FAM19A4/miR124-2 hypermethylation occurs exclusively in tumor samples and that methylation levels are significantly higher in HPV-driven OPCs than in HPV-negative OPCs.

Our results indicate that active CIN2 surveillance could be implemented for women up to 45 years, after selection according to anatomo-clinical criteria and biomarker status. To improve feasibility, the biomarkers can be used sequentially, taking advantage of the HPV genotyping available in primary screening tests, and eventually refining the selection by using the other biomarkers in selected subgroups.

Despite wide confidence intervals, the three-gene methylation test serves as a promising prognostic tool for cancer risk stratification in patients with vulvar HSIL. Patients with methylation-negative HSIL carry a low cancer risk, allowing for more conservative management strategies. This approach may help avoid overtreatment, reducing morbidity and improve quality of life.

Further, a network of genes and their targeting microRNAs (miRNAs) revealed that miRNAs hsa-let-7b-5p, hsa-miR-27a-3p and hsa-miR-124-3p, had the highest interactions with genes. The predicted genes and miRNAs might be worthy prognostic markers and open the possibilities to understand the underlying pathways and recognize therapeutic targets for aggressive OSCC.

Methylation markers, particularly METloc001/METloc002, may be useful for risk-based management of women with a TZ3 at colposcopy.

Antiproliferative effect of abemaciclib, doxorubicin, cisplatin, and temozolomide (TMZ) were detected by MTT method. Increased expression levels of hsa-mir-18a-5p and hsa-miR-124-3p were detected in all drug-treated groups compared to the control group. Our results highlight the potential of abemaciclib as a promising treatment strategy for NB, particularly when used in combination with other therapies to overcome resistance and improve clinical outcomes.

The detection in human blood samples combined with cross-analysis involving H. pylori infection, the expression levels of CagA and clinical markers underscored the significance and effectiveness of these specific miRNAs in early diagnosis and monitoring of gastric carcinoma. This study identified five potential blood miRNA biomarkers for GC through bioinformatics analysis coupled with detection in human blood samples, thus providing new possibilities for important biomarkers related to diagnosis and prognosis of GC.

Furthermore, HPV16's association with hypermethylation suggests its involvement in oral carcinogenesis. To confirm these results and gain further insight into HPV's role in methylation impairment, the sample size will be increased.

FAM19A4 achieved the best performance for the prediction of CIN2+ (ROC: 0.64) and CIN3+ lesions (ROC: 0.73). We hypothesize that while not suitable as stand-alone diagnostic tools, such biomarkers may aid in stratifying patients and optimizing referral decisions, pending further validation in larger, population-based cohorts.